🔗 Share this article

While the US proceeds with historic revisions to its vaccination schedules, a particular individual has surfaced in a surprising turn: Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by casting doubt on coronavirus vaccines during the pandemic and has concentrated on possible fatalities after Covid vaccination in her short time at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Vaccine Schedule

Health officials were set to reveal sweeping changes to the pediatric vaccination calendar in December, bringing the US with the Danish immunization schedule, sources say – a significant shift that would put the US out of step with many the international standard with insufficient data for benefit. The announcement has been postponed until the next year.

Rather than the director of the vaccine center, Tracy Beth Høeg is listed to address the audience at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the center this year.

A Shift at the FDA

Høeg's temporary position may indicate a strengthened alliance between the drug and biologics centers as Dr. Høeg and Prasad solidify control at the regulatory agency – and it points to a greater focus upon dismantling already-approved vaccines at the FDA.

The new acting director has often pushed for halting certain pediatric vaccine recommendations in the US to become more like the Danish model, a nation with comprehensive healthcare and a number of inhabitants approximately the size of Wisconsin’s.

So far statements, she has continued to focus on vaccination policy – traditionally the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Concerns Over Expertise

The appointee has little discernible experience in drug development, regulation or management, which has been typical for previous leaders of the biologics center. She has worked at the FDA as a key advisor to the FDA chief and CBER since March.

“It seems she lacks to have the requisite experience” for leading the CDER, remarked Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in running a major agency. She has no expertise in drug approvals.”

Previous heads of CBER would “be deeply familiar with laws and regulations and the research of drug development”, noted Janet Woodcock. “Objectively, she lacks the sort of resume that prior appointees who ran CBER have had.”

This division has an immense range of responsibilities at the FDA, she pointed out.

“Everybody just pays attention on the new drug program, but the generic program clears a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and other areas, and each of these have to be supervised,” Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial administrative aspect to the position, which manages in excess of 5,000 employees. “It is a huge leadership role, if you execute it properly,” Woodcock concluded.

Response and Disputed Initiatives

In response to concerns about Høeg’s credentials and whether this appointment signifies greater collaboration among regulatory chiefs on vaccines, a spokesperson responded that the “concerns are based on flawed assumptions”.

“This background matches the responsibilities of her job,” the official said, citing the period Dr. Høeg spent advising the FDA commissioner on “drug safety and oversight research, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg takes over the agency head's recently launched priority voucher program, a controversial one-day drug-approval program that apparently concerned her preceding directors. “By what process are these drugs being selected for this fast-track system? Who is making the calls?” Howard questioned. “There is a lot of lack of transparency happening at the regulatory body right now.”

In general, he said, “the Food and Drug Administration seems to be moving towards more relaxed oversight of pharmaceuticals, except for vaccines.”

Public Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a more established, if concerning, history, critics have noted. She authored a research paper using unconfirmed volunteer-provided data to determine the incidence of myocarditis after COVID-19 immunization. She advised the state of Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccines are riskier than they are.

Included in her “desired changes” for the current government encompassed revising regulations for new vaccines and discontinuing “optional” immunizations, she said post-election on a online show. At the agency, Dr. Høeg has allegedly floated the idea of excluding adolescent males from receiving Covid vaccinations.

“She’s an all-around ideologue who begins with her beliefs and reverse-engineers to accommodate the science in a very deceptive, dishonest way,” Dr. Howard argued.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined fellow dissenters, {like|